StockData
Cadrenal Therapeutics, Inc. logo

Cadrenal Therapeutics, Inc. (CVKD) stock

CVKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/30
$1.88+0.48 (+34.29%)

Close on Nov 17, 2026Market cap $6.71MP/E –Yield 877.66%

Cadrenal Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Cadrenal Therapeutics's enterprise value was $2.10M on Nov 11, 2026, against $15.48M a year earlier. Over the last 4 years it ranged from -$3.12M to $23.85M, with a median of $10.11M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$2.10M-79.2%
2025Dec 31, 2025$10.11M-25.3%
2024Dec 31, 2024$13.53M+2473.7%
2023Dec 29, 2023$525.57K–

More Cadrenal Therapeutics figures

See a number that looks wrong?